FDA Approval of 3-Month Formulation CAMCEVI and Expansion of Prostate Cancer Treatment Options

Foresee Pharmaceuticals, a Taiwanese company, has received approval from the U.S. Food and Drug Administration (FDA) for its prostate cancer treatment, CAMCEVI ETM (leuprolide acetate) 21mg, under NDA 219745. This approval follows the 2021 approval of the 6-month formulation CAMCEVI 42mg and offers a new option with a shorter administration cycle. This GnRH receptor agonist is expected to significantly enhance treatment schedule flexibility for both patients and healthcare providers. By allowing for customized adjustments to the frequency of hospital visits, it is anticipated to improve the quality of life and treatment adherence for patients with advanced cancer.

Proven Efficacy Based on Robust Phase 3 Clinical Data

This approval is based on the strong results from a Phase 3 clinical trial (NCT03261999) involving 144 patients with advanced prostate cancer. The trial demonstrated that 97.9% of patients in the treatment group achieved and maintained serum testosterone levels below 50 ng/dL within 28 days of administration, effectively suppressing testosterone to castration levels. This consistent androgen suppression is a key indicator of tumor growth inhibition in advanced prostate cancer, and CAMCEVI's unique stabilized injectable formulation (SIF) platform technology effectively ensures uniform drug release. This addresses the issue of inconsistent initial drug release observed with existing treatments, significantly reducing the risk of adverse effects.

Global Partnerships and Financial Value of Commercialization Milestones

Foresee Pharmaceuticals is pursuing the commercialization of CAMCEVI through licensing agreements with Accord Healthcare and Accord BioPharma. The U.S. market agreement includes an upfront payment of $10 million and milestones totaling $207 million, for a total of $217 million, while agreements for other regions, including Europe, are valued at up to $86 million. As the partner companies will bear the overall costs of marketing and distribution, Foresee can benefit from double-digit royalties and finished product supply revenue based on sales performance without incurring significant fixed costs. This 3-month formulation approval fulfills a key development milestone specified in the agreements with both companies, which will improve the company's short-term financial health.

Competitiveness and Prospects in the Prostate Cancer Hormone Therapy Market

The global leuprolide market is estimated at $2.7 billion to $4.3 billion by 2026 and plays a central role in hormone therapy for advanced prostate cancer. CAMCEVI will compete directly with existing standard treatments such as AbbVie's Lupron Depot and Tolmar's Eligard. In particular, its unique convenience as a ready-to-use formulation that requires no mixing offers the advantage of preventing medication errors and maximizing patient convenience. This strength is expected to be a key catalyst in driving the next generation of the leuprolide market and expanding CAMCEVI's market share.